ESC Action Center
Welcome to the ESC Action Center, where you’ll find breaking news and insights from the 2024 European Society of Cardiology (ESC) Congress. Explore pivotal presentations, innovative research findings, and emerging treatments to stay at the forefront of the latest advancements in cardiology.
Episodes 1-8 of 8
Intensive and early lowering of atherogenic lipids after MI
ESC Action CenterIntensive and early lowering of atherogenic lipids after MI
Class I recommendation to use the AF-CARE pathway in new ESC guidelines for AF
ESC Action CenterClass I recommendation to use the AF-CARE pathway in new ESC guidelines for AF
In patients with HFmrEF/HFpEF, finerenone reduces composite of CV death or total HF events
ESC Action CenterIn patients with HFmrEF/HFpEF, finerenone reduces composite of CV death or total HF events
Disease-modifying effects of finerenone in CKM syndrome
ESC Action CenterDisease-modifying effects of finerenone in CKM syndrome
Does taking antihypertensive medication in the evening reduce CV events?
ESC Action CenterDoes taking antihypertensive medication in the evening reduce CV events?
Timing of antihypertensive medications does not affect CVD risk
ESC Action CenterTiming of antihypertensive medications does not affect CVD risk
Continuation or interruption of β-blocker therapy in stable post-MI patients?
ESC Action CenterContinuation or interruption of β-blocker therapy in stable post-MI patients?
Remarkable results in phase 3 study with vutrisiran in patients with ATTR-CM
ESC Action CenterRemarkable results in phase 3 study with vutrisiran in patients with ATTR-CM
